<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364367">
  <stage>Registered</stage>
  <submitdate>19/06/2013</submitdate>
  <approvaldate>12/07/2013</approvaldate>
  <actrnumber>ACTRN12613000780752</actrnumber>
  <trial_identification>
    <studytitle>Transcranial magnetic stimulation for obsessive compulsive disorder </studytitle>
    <scientifictitle>Neuronavigationally Targeted rTMS in Treatment Resistant Obsessive Compulsive Disorder</scientifictitle>
    <utrn />
    <trialacronym>rTMS for OCD</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obsessive compulsive disorder </healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will receive a 30-minute repetitive transcranial magnetic stimulation (rTMS) treatment each week day for four weeks (20 treatments in total).  

rTMS will be delivered with a Medtronic Magpro stimulator at 1 Hz and 120% of motor threshold in one continuous train of 30 minutes duration (1800 pulses per day).  </interventions>
    <comparator>The clinical efficacy of rTMS delivered to two different brain areas will be compared: 

1. right hemispheric premotor cortex 

versus 

2. bilateral supplementary motor area 

Each participant will receive treatment at one (not both) of these brain sites. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>YaleBrown ObsessiveCompulsive Scale</outcome>
      <timepoint>Following 20th treatment. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Beck Depression Inventory - II</outcome>
      <timepoint>Following 20th treatment </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Beck Anxiety Inventory</outcome>
      <timepoint>Following 20th treatment </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impression </outcome>
      <timepoint>Following 20th treatment </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Have a DSM-IV diagnosis of an obsessive compulsive disorder. 

2. Have treatment resistance as defined by a failure to respond to at least two trials of adequate dose and duration of appropriate medications (serotonin reuptake inhibitor medications or clomipramine). 

3. Have had no increase or initiation of new medication therapy in the 6 weeks prior to screening. 
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating.

2. Have a current DSM IV diagnosis of substance abuse or dependence disorder, a diagnosis of a personality disorder or another axis 1 disorder except depression or another anxiety disorder. 

3. Any contraindication to TMS or MRI scanning.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/08/2013</anticipatedstartdate>
    <actualstartdate>22/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash Alfred Psychiatry Research Centre</primarysponsorname>
    <primarysponsoraddress>Level 4, 607 St Kilda Rd
Prahran VIC
3181 </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Monash Alfred Psychiatry Research Centre</fundingname>
      <fundingaddress>Level 4, 607 St Kilda Rd
Prahran VIC
3181 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Monash Clinical Imaging and Neuroscience

</fundingname>
      <fundingaddress>Monash Biomedical Imaging
770 Blackburn Rd
Clayton VIC
3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A number of small studies have investigated the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for OCD by stimulating an area of the frontal lobe called the DLPFC. On the whole, the results of these studies have not been encouraging. 

The current project aims to compare the clinical efficacy of rTMS for OCD at two promising novel treatment targets: right sided premotor cortex versus bilateral supplementary motor area. 

Participation in the trial involves having two MRI brain scans and four weeks of inpatient rTMS treatment in Melbourne, Australia. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Melbourne Clinic Research Ethics Committee</ethicname>
      <ethicaddress>130 Church Street
Richmond, 3121
VIC</ethicaddress>
      <ethicapprovaldate>21/08/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>12/06/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Paul Fitzgerald</name>
      <address>Monash Alfred Psychiatry Research Centre (MAPrc)
Level 4, 607 St Kilda Rd
Prahran, 3004
VIC</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>paul.fitzgerald@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rebecca Segrave</name>
      <address>MAPrc
Level 4, 607 St Kilda Rd
Prahran, 3004
VIC</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>rebecca.segrave@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rebecca Segrave</name>
      <address>MAPrc
Level 4, 607 St Kilda Rd
Prahran, 3004
VIC</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>rebecca.segrave@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>